Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.

The original article [1] contains an error in Fig. 2 whereby Fig. 2D has mistakenly been omitted. Fig. 2 can be viewed in its entirety - including Fig. 2D - in this Correction article.

Correction to: J Hematol Oncol (2019) 12:56

https://doi.org/10.1186/s13045-019-0740-7

The original article [1] contains an error in Fig. 2 whereby Fig. 2d has mistakenly been omitted. Figure 2 can be viewed in its entirety – including Fig. 2d – in this Correction article.

Fig. 2

Characterization of tumor derived exosomes and EVs. The size and morphology of exosomes were evaluated by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) (a) and transmission electron microscopy (TEM) (b), respectively. The yield of DNA was 3.4-fold higher in LXY30-enriched exosomes than in S-LXY30-enriched exosomes (3.4 ± 0.7 vs 1.0 ± 0.2 ng/μL, p = 0.014) (c). Driven mutations (EGFR L858R and T790 M in H1975) were detected by PCR and Sanger sequencing in the DNA isolated from LXY30 exosomes (d)